AbbVie Inc. (ABBV)
Pre-market:
| Previous close | 164.25 |
| Open | 164.96 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 164.43 - 167.44 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,637,629 |
| Market cap | 291.555B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 60.54 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.77%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- Fool.co.uk
3 top US dividend stocks for value investors to consider in 2024
I’m searching far and wide to find the best dividend stocks that money can buy. Do the Americans have more to offer when it comes to value investing? The post 3 top US dividend stocks for value investors to consider in 2024 appeared first on The Motley Fool UK.
- Benzinga
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without tr
- Zacks
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
